Literature DB >> 21664680

Vaccine production, distribution, access, and uptake.

Jon Smith1, Marc Lipsitch, Jeffrey W Almond.   

Abstract

For human vaccines to be available on a global scale, complex production methods, meticulous quality control, and reliable distribution channels are needed to ensure that the products are potent and effective at the point of use. The technologies used to manufacture different types of vaccines can strongly affect vaccine cost, ease of industrial scale-up, stability, and, ultimately, worldwide availability. The complexity of manufacturing is compounded by the need for different formulations in different countries and age-groups. Reliable vaccine production in appropriate quantities and at affordable prices is the cornerstone of developing global vaccination policies. However, to ensure optimum access and uptake, strong partnerships are needed between private manufacturers, regulatory authorities, and national and international public health services. For vaccines whose supply is insufficient to meet demand, prioritisation of target groups can increase the effect of these vaccines. In this report, we draw from our experience of vaccine development and focus on influenza vaccines as an example to consider production, distribution, access, and other factors that affect vaccine uptake and population-level effectiveness.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21664680      PMCID: PMC3164579          DOI: 10.1016/S0140-6736(11)60478-9

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  47 in total

1.  Estimating the costs of achieving the WHO-UNICEF Global Immunization Vision and Strategy, 2006-2015.

Authors:  Lara J Wolfson; François Gasse; Shook-Pui Lee-Martin; Patrick Lydon; Ahmed Magan; Abdelmajid Tibouti; Benjamin Johns; Raymond Hutubessy; Peter Salama; Jean-Marie Okwo-Bele
Journal:  Bull World Health Organ       Date:  2008-01       Impact factor: 9.408

2.  Suitability of PER.C6 cells to generate epidemic and pandemic influenza vaccine strains by reverse genetics.

Authors:  W Koudstaal; L Hartgroves; M Havenga; I Legastelois; C Ophorst; M Sieuwerts; D Zuijdgeest; R Vogels; J Custers; E de Boer-Luijtze; O de Leeuw; L Cornelissen; J Goudsmit; W Barclay
Journal:  Vaccine       Date:  2009-02-20       Impact factor: 3.641

Review 3.  Trivalent MDCK cell culture-derived influenza vaccine Optaflu (Novartis Vaccines).

Authors:  Alexander Doroshenko; Scott A Halperin
Journal:  Expert Rev Vaccines       Date:  2009-06       Impact factor: 5.217

4.  Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents.

Authors:  Harry Keyserling; Thomas Papa; Katalin Koranyi; Robert Ryall; Ehab Bassily; Michael J Bybel; Kevin Sullivan; Gregory Gilmet; Al Reinhardt
Journal:  Arch Pediatr Adolesc Med       Date:  2005-10

Review 5.  The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza.

Authors:  Marc-André D'Aoust; Manon M-J Couture; Nathalie Charland; Sonia Trépanier; Nathalie Landry; Frédéric Ors; Louis-P Vézina
Journal:  Plant Biotechnol J       Date:  2010-02-18       Impact factor: 9.803

6.  Efficacy of an acellular pertussis vaccine among adolescents and adults.

Authors:  Joel I Ward; James D Cherry; Swei-Ju Chang; Susan Partridge; Hang Lee; John Treanor; David P Greenberg; Wendy Keitel; Stephen Barenkamp; David I Bernstein; Robert Edelman; Kathryn Edwards
Journal:  N Engl J Med       Date:  2005-10-13       Impact factor: 91.245

7.  Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein.

Authors:  V A Slepushkin; J M Katz; R A Black; W C Gamble; P A Rota; N J Cox
Journal:  Vaccine       Date:  1995       Impact factor: 3.641

8.  Reproductive numbers, epidemic spread and control in a community of households.

Authors:  E Goldstein; K Paur; C Fraser; E Kenah; J Wallinga; M Lipsitch
Journal:  Math Biosci       Date:  2009-06-25       Impact factor: 2.144

9.  Strategies for mitigating an influenza pandemic.

Authors:  Neil M Ferguson; Derek A T Cummings; Christophe Fraser; James C Cajka; Philip C Cooley; Donald S Burke
Journal:  Nature       Date:  2006-04-26       Impact factor: 49.962

10.  Estimation of the reproductive number and the serial interval in early phase of the 2009 influenza A/H1N1 pandemic in the USA.

Authors:  Laura Forsberg White; Jacco Wallinga; Lyn Finelli; Carrie Reed; Steven Riley; Marc Lipsitch; Marcello Pagano
Journal:  Influenza Other Respir Viruses       Date:  2009-11       Impact factor: 4.380

View more
  24 in total

1.  Evaluation of the 2010 National Vaccine Plan Mid-course Review: Recommendations From the National Vaccine Advisory Committee: Approved by the National Vaccine Advisory Committee on February 7, 2017.

Authors: 
Journal:  Public Health Rep       Date:  2017-06-23       Impact factor: 2.792

2.  Enhancing the work of the Department of Health and Human Services national vaccine program in global immunization: recommendations of the National Vaccine Advisory Committee: approved by the National Vaccine Advisory Committee on September 12, 2013.

Authors: 
Journal:  Public Health Rep       Date:  2014       Impact factor: 2.792

3.  Preexisting subtype immunodominance shapes memory B cell recall response to influenza vaccination.

Authors:  Rodrigo B Abreu; Greg A Kirchenbaum; Emily F Clutter; Giuseppe A Sautto; Ted M Ross
Journal:  JCI Insight       Date:  2020-01-16

4.  A Needs-Based Analysis of Teaching on Vaccinations and COVID-19 in German Medical Schools.

Authors:  Franziska Baessler; Ali Zafar; Katharina Mengler; Ricarda Nadine Natus; Anne Josephine Dutt; Manuel Kuhlmann; Emre Çinkaya; Simon Hennes
Journal:  Vaccines (Basel)       Date:  2022-06-19

5.  Bivalent H1 and H3 COBRA Recombinant Hemagglutinin Vaccines Elicit Seroprotective Antibodies against H1N1 and H3N2 Influenza Viruses from 2009 to 2019.

Authors:  James D Allen; Ted M Ross
Journal:  J Virol       Date:  2022-03-15       Impact factor: 6.549

6.  A novel hepatitis B vaccine containing Advax™, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing.

Authors:  Fadi Saade; Yoshikazu Honda-Okubo; Samay Trec; Nikolai Petrovsky
Journal:  Vaccine       Date:  2013-01-07       Impact factor: 3.641

Review 7.  Looking beyond COVID-19 vaccine phase 3 trials.

Authors:  Jerome H Kim; Florian Marks; John D Clemens
Journal:  Nat Med       Date:  2021-01-19       Impact factor: 53.440

8.  The development of COVID-19 vaccines in the United States: Why and how so fast?

Authors:  Barbara J Kuter; Paul A Offit; Gregory A Poland
Journal:  Vaccine       Date:  2021-03-26       Impact factor: 3.641

9.  Targeted Vaccine Allocation Could Increase the COVID-19 Vaccine Benefits Amidst Its Lack of Availability: A Mathematical Modeling Study in Indonesia.

Authors:  Ahmad Fuady; Nuning Nuraini; Kamal K Sukandar; Bony W Lestari
Journal:  Vaccines (Basel)       Date:  2021-05-06

10.  Socioeconomic, cultural and behavioural features of prior and anticipated influenza vaccine uptake in urban and rural Pune district, India: a mixed-methods case study.

Authors:  Abhay Kudale; Vidula Shridhar Purohit; Neisha Sundaram; Christian Schaetti; Mitchell G Weiss
Journal:  BMJ Open       Date:  2013-02-13       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.